CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials.
Hopewell S., Chan A-W., Collins GS., Hróbjartsson A., Moher D., Schulz KF., Tunn R., Aggarwal R., Berkwits M., Berlin JA., Bhandari N., Butcher NJ., Campbell MK., Chidebe RCW., Elbourne D., Farmer A., Fergusson DA., Golub RM., Goodman SN., Hoffmann TC., Ioannidis JPA., Kahan BC., Knowles RL., Lamb SE., Lewis S., Loder E., Offringa M., Ravaud P., Richards DP., Rockhold FW., Schriger DL., Siegfried NL., Staniszewska S., Taylor RS., Thabane L., Torgerson D., Vohra S., White IR., Boutron I.
Critical appraisal of the quality of randomised trials is possible only if their design, conduct, analysis, and results are completely and accurately reported. Without transparent reporting of the methods and results, readers will not be able to fully evaluate the reliability and validity of trial findings. The CONSORT (Consolidated Standards of Reporting Trials) statement aims to improve the quality of reporting and provides a minimum set of items to be included in a report of a randomised trial. CONSORT was first published in 1996 and was updated in 2001 and 2010. CONSORT comprises a checklist of essential items that should be included in reports of randomised trials and a diagram for documenting the flow of participants through a trial. The CONSORT statement has been updated (CONSORT 2025) to reflect recent methodological advancements and feedback from end users, ensuring that it remains fit for purpose. Here, we present the updated CONSORT explanation and elaboration document, which has been extensively revised and describes the rationale and scientific background for each CONSORT 2025 checklist item and provides published examples of good reporting. The objective is to enhance the use, understanding, and dissemination of CONSORT 2025 and provide guidance to authors about how to improve the reporting of their trials and ensure trial reports are complete, and transparent.